Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

TNF-α stimulation of THP1 monocytes:5.1 pM

METHODS: ARPE cells were co-cultured with MT2, TL-Om1 or Jurkat cells and treated with Adalimumab (0.1-10 µg/mL) for 48 h. Supernatants were extracted to measure the levels of inflammatory cytokines using CBA human inflammation cytokine kits.
RESULTS: The levels of IL-6, IL-10 and IL-8 production did not change with the addition of Adalimumab. adalimumab decreased tumor necrosis factor (TNF) secretion in a concentration-dependent manner, and TNF was not detected at Adalimumab ≥1.0 µg/mL.[1]
METHODS: CD4+ T cells were treated with Adalimumab (1 µg/mL) and aCD3/CD28 mAb for 3 days, then stimulated with PMA/ionomycin in the presence of GolgiStop for 3 h. IL-10 expression was detected using mass spectrometry cytometry (CyTOF).
RESULTS: Adalimumab treatment resulted in the induction of IL-10 in multiple CD4+ T cell subsets. [2]

METHODS: To study the effects on the human autosomal recessive RP mouse model, Adalimumab (3 mg/kg) was administered intraperitoneally to rd10 mice, a human autosomal recessive retinitis pigmentosa model, every three days for nine days.
RESULTS: Adalimumab reduced photoreceptor cell death by scoring the number of TUNEL-positive cells. adalimumab also improved the antioxidant response by restoring total antioxidant capacity and superoxide dismutase activity. adalimumab normalized the energy and metabolism patterns in the retina of rd10 mice. [3]

Objective: Adalimumab induces apoptosis of THP-1 cells. Concentrations: 10μg/mL. Incubation Time: 6, 12, 18, 24, 30 hours. Method: THP-1 cells (0.5×106) were incubated with anti-FcRI mAb and anti-FcRII mAb, and then cultured with adalimumab, infliximab, huIgG or vehicle (PBS) alone as indicated. LPS (1μg/mL) was added in all culture conditions. Apoptosis was analyzed at different time points by staining with annexin V-FITC and propidium iodide, Apo2.7-PE-conjugated antibody, or 7AAD.

Objective: The distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. Formulation: PBS. Dosages: 2 mg/kg

Human

Monoclonal

Unconjugated